CompletedNCT00700427
This study is completed. It focuses on ADHD and currently lists study information in Austria, Belgium, Finland, France, Germany, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
In BelgiumADHDOtherFrom 18 Years to 50 Years
- Countries
- France, United Kingdom, Switzerland, ...
- Sponsor
- Eli Lilly and Company
- Condition
- ADHD
OngoingEUCTR 2018-000821-29
This study is ongoing in the United Kingdom, in Belgium, in Germany, .... It focuses on ADHD.
In BelgiumADHDOther
- Countries
- United Kingdom, Belgium, Germany, ...
- Sponsor
- Takeda Development Center Americas, Inc.
- Condition
- ADHD
CompletedEUCTR 2022-000439-22
This study is completed in Belgium, in Sweden, in Czechia, .... It is testing Efficacy, Safety, and Tolerability of Aticaprant 10 mg for Depression.
In BelgiumDepressionOther
- Countries
- Belgium, Sweden, Czechia, ...
- Sponsor
- Janssen-Cilag International NV
- Condition
- Depression
TerminatedNCT06514742
This study was terminated in the United States, in Belgium, in Brazil, .... It is testing Aticaprant 10 mg for depression.
In BelgiumDepressionOtherFrom 18 Years to 64 Years
- Countries
- United States, Belgium, Brazil, ...
- Sponsor
- Janssen Research & Development, LLC
- Condition
- Depression
TerminatedNCT05518149
This study was terminated in the United States, in Australia, in France, .... It is testing aticaprant for depression.
In BelgiumDepressionOtherFrom 18 Years to 74 Years
- Countries
- United States, Australia, France, ...
- Sponsor
- Janssen Research & Development, LLC
- Condition
- Depression
TerminatedNCT06635135
This study was terminated in the United States, in France, in Belgium, .... It is testing aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms for depression.
In BelgiumDepressionOtherFrom 18 Years to 64 Years
- Countries
- United States, France, Belgium, ...
- Sponsor
- Janssen Research & Development, LLC
- Condition
- Depression
CompletedNCT04085172
This study is completed in the United States, in the United Kingdom, in Belgium, .... It is testing TAK-503 for ADHD.
In BelgiumADHDOtherFrom 6 Years to 17 Years
- Countries
- United States, United Kingdom, Belgium, ...
- Sponsor
- Shire
- Condition
- ADHD
CompletedNCT00714688
This study is completed in France, in the United Kingdom, in Switzerland, .... It is testing Effectiveness and Safety of Prolonged Release OROS Methylphenidate for ADHD.
In BelgiumADHDOtherFrom 18 Years to 65 Years
- Countries
- France, United Kingdom, Switzerland, ...
- Sponsor
- Janssen-Cilag International NV
- Condition
- ADHD
CompletedNCT06280235
This study is completed. It focuses on depression and currently lists study information in Belgium, Bulgaria, China, Czech Republic, Germany, Japan, and the United States.
In BelgiumDepressionOtherFrom 18 Years to 65 Years
- Countries
- United States, Belgium, Bulgaria, ...
- Sponsor
- Boehringer Ingelheim
- Condition
- Depression
TerminatedNCT05211947
This study was terminated in the United States, in Australia, in France, .... It focuses on schizophrenia.
In BelgiumSchizophreniaOtherFrom 18 Years to 51 Years
- Countries
- United States, Australia, France, ...
- Sponsor
- Boehringer Ingelheim
- Condition
- Schizophrenia
CompletedNCT03809325
This study is completed in France, in the United Kingdom, in Belgium, .... It focuses on Schizophrenia.
In BelgiumSchizophreniaOtherOver 18 Years
- Countries
- France, United Kingdom, Belgium, ...
- Sponsor
- Janssen-Cilag International NV
- Condition
- Schizophrenia
CompletedNCT01500694
This study is completed. It focuses on ADHD and currently lists study information in Austria, Belgium, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Spain, Sweden, Ukraine, and the United Kingdom.
In BelgiumADHDOtherFrom 6 Years to 17 Years
- Countries
- France, United Kingdom, Belgium, ...
- Sponsor
- Shire
- Condition
- ADHD